Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T21:33:39.265Z.
Calculation as of: 2026-10-06T21:33:39.265Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d00a9c235f8f3f2200d332a4911885706ef223ec632fccfa45bb3326c1a5dd06
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$95.14M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$93.96M
Price/OCF Ratio
0.01
TTM Avg
1.89
3Y Avg
1.89
5Y Avg
1.89
Market Cap
$102.75M
Price/OCF Ratio
N/A
TTM Avg
17.45
3Y Avg
17.45
5Y Avg
17.45
Market Cap
$103.14M
Price/OCF Ratio
N/A
TTM Avg
8.98
3Y Avg
8.98
5Y Avg
8.98
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| PolyPid Ltd. (PYPD) | $97.90M | N/A | N/A | N/A | N/A |
| Conexeu Sciences Inc. (CNXU)vs › | $97.94M | N/A | N/A | N/A | N/A |
| Korro Bio, Inc. (KRRO)vs › | $97.14M | N/A | N/A | N/A | N/A |
| OnKure Therapeutics, Inc. (OKUR)vs › | $99.62M | N/A | N/A | N/A | N/A |
| Milestone Pharmaceuticals Inc. (MIST)vs › | $95.14M | N/A | N/A | N/A | N/A |
| The Joint Corp. (JYNT)vs › | $101.36M | 18.82 | 39.64 | 28.03 | 30.91 |
| Park Dental Partners, Inc. Common Stock (PARK)vs › | $93.96M | 0.01 | 1.89 | 1.89 | 1.89 |
| Anixa Biosciences, Inc. (ANIX)vs › | $102.75M | N/A | 17.45 | 17.45 | 17.45 |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $103.14M | N/A | 8.98 | 8.98 | 8.98 |
| Definitive Healthcare Corp. (DH)vs › | $104.26M | 2.52 | 3.01 | 10.71 | 28.96 |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
